ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Effective"

  • Abstract Number: 2628 • 2013 ACR/ARHP Annual Meeting

    Immunogenicity Of Infliximab Modulates Efficacy and Safety In Behcet’s Disease Patients With Uveitis

    Mitsuhiro Takeno1, Kayo Terauchi1, Yohei Kirino1,2, Ryusuke Yoshimi1, Nobuhisa Mizuki2, Etsuko Shibuya3 and Yoshiaki Ishigatsubo2, 1Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan, 2Yokohama City University Graduate School of Medicine, Yokohama, Japan, 3Department of Ophthalmology and Visual Science, Yokohama City University Graduate School of Medicine, Yokohama, Japan

    Background/Purpose: Infliximab (IFX) suppresses ocular attacks in Behcet’s disease (BD) with uveitis, resulting in favorable long-term visual prognosis. However, some patients had ocular attacks which…
  • Abstract Number: 2384 • 2013 ACR/ARHP Annual Meeting

    Variability In Patient Characteristics and Outcomes In Rheumatoid Arthritis Upon Infliximab Treatment Based On The Size Of Biologic Treatment Registry Site

    J. Carter Thorne1, William G. Bensen2, Sanjay Dixit3, Rafat Y. Faraawi3,4, Dalton E. Sholter5, Maqbool K. Sheriff6, Philip Baer7, Denis Choquette8, Boulos Haraoui8,9, Algis Jovaisas10, Emmanouil Rampakakis11,12, John S. Sampalis11,12, May Shawi13, Francois Nantel14, Allen J. Lehman15 and Susan M. Otawa15, 1Southlake Regional Health Centre, Newmarket, ON, Canada, 2Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, 3McMaster University, Hamilton, ON, Canada, 4Rheumatologist, KW Musculoskeletal Research Inc., Kitchener, ON, Canada, 5Rheumatology Associates, Edmonton, AB, Canada, 6Nanaimo Regional General Hospital, Nanaimo, BC, Canada, 7Private Practice, Scarborough, ON, Canada, 8Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, 9Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada, 10Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada, 11JSS Medical Research, Montreal, QC, Canada, 12Jewish General Hospital, McGill University, Montreal, QC, Canada, 13Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada, 14Janssen Inc., Toronto, ON, Canada, 15Medical Affairs, Janssen Inc., Toronto, ON, Canada

    Background/Purpose: Efficacy of TNFi agents in the management of rheumatoid arthritis (RA) has been demonstrated in numerous controlled clinical trials. Variations with respect to patient…
  • Abstract Number: 1550 • 2013 ACR/ARHP Annual Meeting

    Validation Of The Ankylosing Spondylitis Disease Activity Score and Effectiveness Of Infliximab In The Treatment Of Ankylosing Spondylitis Over 4 Years: The Canadian Experience

    Proton Rahman1, Denis Choquette2, Majed M. Khraishi3, William G. Bensen4, Saeed A. Shaikh5, Dalton E. Sholter6, Maqbool K. Sheriff7, Emmanouil Rampakakis8, John S. Sampalis8, Francois Nantel9, Susan M. Otawa10, Allen J. Lehman10 and May Shawi11, 1Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, 2Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, 3Nexus Clinical Research, St John's, NF, Canada, 4Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, 5Medicine, McMaster University, St Catharines, ON, Canada, 6Rheumatology Associates, Edmonton, AB, Canada, 7Nanaimo Regional General Hospital, Nanaimo, BC, Canada, 8JSS Medical Research, Montreal, QC, Canada, 9Janssen Inc., Toronto, ON, Canada, 10Medical Affairs, Janssen Inc., Toronto, ON, Canada, 11Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada

    Background/Purpose: The efficacy of anti-TNF in the management of Ankylosing Spondylitis (AS) has been demonstrated in numerous controlled clinical trials. The objective of this study…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology